Tag Archives: treatment

FDA Approves Bylvay (odevixibat) for the Treatment of Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

FDA Approves Bylvay (odevixibat) for the Treatment of Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) BOSTON, July 20, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced U.S. Food & Drug Administration (FDA) approval of Bylvay (odevixibat), the first drug approved for the treatment of pruritus in… Read More »

FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes WHIPPANY, N.J.– July 9, 2021 (BUSINESS WIRE)– Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained… Read More »

With ‘evolved’ treatment landscape, Merck pulls Keytruda’s FDA nod in third-line stomach cancer

Two months after a key FDA panel voted down Merck’s conditional nod for Keytruda as a third-line treatment for certain stomach cancer patients, the company says it’s pulling the plug on the indication.  Following consultation with the FDA, Merck on Thursday said it will voluntarily withdraw its U.S. accelerated approval for Keytruda as a third-line… Read More »

In Women with Opioid Use Disorder, Treatment Initiated During Pregnancy May Improve Postpartum Outcomes

According to a recent analysis of national data by the Centers for Disease Control, the number of pregnant women with opioid use disorder (as documented at the time of delivery) more than quadrupled from 1999 through 2014. While many women are able to decrease or abstain from opioid use during pregnancy, the first year postpartum… Read More »